Analysts have been eager to weigh in on the Healthcare sector with new ratings on Legend Biotech (LEGN – Research Report), IGM Biosciences (IGMS – Research Report) and Elanco Animal Health (ELAN – Research Report).
Legend Biotech (LEGN)
J.P. Morgan analyst Jessica Fye maintained a Buy rating on Legend Biotech on May 7 and set a price target of $79.00. The company’s shares closed last Wednesday at $45.72, close to its 52-week low of $42.08.
According to TipRanks.com, Fye is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Legend Biotech with a $86.00 average price target, implying an 88.1% upside from current levels. In a report issued on April 23, H.C. Wainwright also reiterated a Buy rating on the stock with a $87.00 price target.
See today’s best-performing stocks on TipRanks >>
IGM Biosciences (IGMS)
In a report released today, Eric Joseph from J.P. Morgan maintained a Hold rating on IGM Biosciences, with a price target of $11.00. The company’s shares closed last Wednesday at $9.34.
According to TipRanks.com, Joseph is a 3-star analyst with an average return of
IGM Biosciences has an analyst consensus of Moderate Buy, with a price target consensus of $20.50.
Elanco Animal Health (ELAN)
J.P. Morgan analyst Chris Schott maintained a Hold rating on Elanco Animal Health today and set a price target of $16.00. The company’s shares closed last Wednesday at $16.89, close to its 52-week high of $17.23.
According to TipRanks.com, Schott is a 3-star analyst with an average return of
Elanco Animal Health has an analyst consensus of Moderate Buy, with a price target consensus of $18.29.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on LEGN:
- Legend Biotech participates in a conference call with JPMorgan
- European Approval for Legend Biotech’s Myeloma Treatment
- Legend Biotech says Carvykti approved by EC for second-line multiple myeloma
- Scotiabank upgrades Legend Biotech on attractive entry point
- Legend Biotech upgraded to Outperform from Sector Perform at Scotiabank
